PriceTargets.com logo

aTyr Pharma - LIFE Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $25.50
  • Forecasted Upside: ∞
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 06/4/2024 10:09 PM ET
+0 (0.00%)
Get New aTyr Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LIFE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LIFE

Analyst Price Target is $25.50
▲ +∞ Upside Potential
This price target is based on 2 analysts offering 12 month price targets for aTyr Pharma in the last 3 months. The average price target is $25.50, with a high forecast of $35.00 and a low forecast of $16.00. The average price target represents a ∞ upside from the last price of $0.00.

This chart shows the closing price for LIFE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in aTyr Pharma. This rating has held steady since June 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$35.00
5/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$35.00
3/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$35.00
3/15/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$19.00 ➝ $16.00
2/21/2024HC WainwrightReiterated RatingBuy ➝ Buy$35.00
9/21/2023HC WainwrightReiterated RatingBuy ➝ Buy$35.00
9/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$35.00
8/10/2023HC WainwrightReiterated RatingBuy ➝ Buy$35.00
7/20/2023Piper SandlerBoost TargetOverweight$13.00 ➝ $20.00
7/5/2023OppenheimerDowngradeOutperform ➝ Market Perform
4/11/2023Piper SandlerBoost TargetOverweight$9.00 ➝ $13.00
3/10/2023HC WainwrightReiterated RatingBuy$35.00
3/10/2023Royal Bank of CanadaReiterated RatingOutperform$19.00
3/6/2023Roth MkmReiterated RatingBuy$9.00
3/3/2023Roth CapitalReiterated RatingBuy
3/2/2023Royal Bank of CanadaLower TargetOutperform$20.00 ➝ $19.00
2/7/2023HC WainwrightReiterated RatingBuy$35.00
8/15/2022Piper SandlerBoost TargetOverweight$11.00 ➝ $14.00
7/21/2022HC WainwrightBoost TargetBuy$11.00 ➝ $35.00
5/18/2022Piper SandlerLower TargetOverweight$19.00 ➝ $11.00
11/11/2021HC WainwrightLower TargetBuy$18.00 ➝ $11.00
10/12/2021Royal Bank of CanadaInitiated CoverageOutperform$22.00
9/21/2021Piper SandlerInitiated CoverageOverweight$19.00
9/14/2021OppenheimerBoost TargetOutperform$14.00 ➝ $20.00
9/13/2021Roth CapitalBoost TargetBuy$20.00 ➝ $21.00
9/13/2021HC WainwrightBoost TargetPositive ➝ Buy$13.00 ➝ $18.00
6/30/2021JonestradingReiterated RatingBuy$15.00
5/18/2021JonestradingInitiated CoverageBuy$15.00
5/10/2021LaidlawInitiated CoverageBuy$18.00
3/30/2021OppenheimerBoost TargetOutperform$12.00 ➝ $14.00
3/24/2021OppenheimerReiterated RatingBuy$12.00 ➝ $14.00
3/16/2021Roth CapitalBoost TargetPositive ➝ Buy$15.00 ➝ $20.00
9/22/2020OppenheimerReiterated RatingBuy
8/17/2020HC WainwrightUpgradeNeutral ➝ Buy$13.00
6/16/2020OppenheimerReiterated RatingBuy$8.00
5/13/2020OppenheimerReiterated RatingBuy$8.00
4/21/2020HC WainwrightReiterated RatingHold
3/27/2020HC WainwrightDowngradeBuy ➝ Neutral
3/4/2020Roth CapitalInitiated CoverageBuy$15.00
3/2/2020OppenheimerInitiated CoverageOutperform$8.00
1/10/2020HC WainwrightReiterated RatingBuy$8.00
12/13/2019HC WainwrightReiterated RatingBuy$8.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.29 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024

Current Sentiment

  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

aTyr Pharma logo
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $1.76
Low: $1.57
High: $2.07

52 Week Range

Now: N/A

Volume

269,400 shs

Average Volume

514,103 shs

Market Capitalization

$131.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19

Frequently Asked Questions

What sell-side analysts currently cover shares of aTyr Pharma?

The following Wall Street sell-side analysts have issued research reports on aTyr Pharma in the last year: HC Wainwright, Royal Bank of Canada, and StockNews.com.
View the latest analyst ratings for LIFE.

What is the current price target for aTyr Pharma?

0 Wall Street analysts have set twelve-month price targets for aTyr Pharma in the last year. Their average twelve-month price target is $25.50. HC Wainwright has the highest price target set, predicting LIFE will reach $35.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $16.00 for aTyr Pharma in the next year.
View the latest price targets for LIFE.

What is the current consensus analyst rating for aTyr Pharma?

aTyr Pharma currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LIFE will outperform the market and that investors should add to their positions of aTyr Pharma.
View the latest ratings for LIFE.

What other companies compete with aTyr Pharma?

Other companies that are similar to aTyr Pharma include Pacific Biosciences of California, Harvard Bioscience, PTC Therapeutics, Sarepta Therapeutics and Thermo Fisher Scientific. Learn More about companies similar to aTyr Pharma.

How do I contact aTyr Pharma's investor relations team?

aTyr Pharma's physical mailing address is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. The biotechnology company's listed phone number is (858) 731-8389 and its investor relations email address is [email protected]. The official website for aTyr Pharma is www.atyrpharma.com. Learn More about contacing aTyr Pharma investor relations.